Unbalanced Expression of the Different Subunits of Elongation Factor 1 in Diabetic Skeletal Muscle

In studies using subtraction cloning to screen for alterations in mRNA expression in skeletal muscle from humans with Type 2 diabetes mellitus and control subjects, one of the most prominent differences was in the mRNA for elongation factor (EF)-1α. With Northern blot analysis, EF-1α expression was...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 98; no. 6; pp. 3422 - 3427
Main Authors Reynet, Christine, Kahn, C. Ronald
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences 13.03.2001
National Acad Sciences
The National Academy of Sciences
Subjects
Online AccessGet full text
ISSN0027-8424
1091-6490
DOI10.1073/pnas.051630398

Cover

More Information
Summary:In studies using subtraction cloning to screen for alterations in mRNA expression in skeletal muscle from humans with Type 2 diabetes mellitus and control subjects, one of the most prominent differences was in the mRNA for elongation factor (EF)-1α. With Northern blot analysis, EF-1α expression was enhanced by 2- to 6-fold in both Types 1 and 2 human diabetics. In contrast, no changes in expression of EF-1β or -γ were noted. We observed similar results in animal models of Type 1 diabetes. EF-1α expression, but not EF-1β or -γ expression, was also enhanced in streptozotocin-induced diabetic rats, and this effect was reversed by insulin treatment. An increased level of EF-1α mRNA was also observed in nonobese diabetic mice. This unbalanced regulation of the expression of the different subunits of EF-1 may contribute to alterations not only in protein synthesis but also in other cellular events observed in the diabetic state.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-2
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
Contributed by C. Ronald Kahn
To whom reprint requests should be addressed at: Research Division, Joslin Diabetes Center, One Joslin Place, Boston, MA 02215. E-mail: c.ronald.kahn@joslin.harvard.edu.
Present address: Diabetes Biology Department, Target Cell Biology Health Care Discovery Novo Nordisk Novo Alle 6A1.069, 2880 Bagsværd, Denmark.
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.051630398